JP2008520697A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520697A5 JP2008520697A5 JP2007543254A JP2007543254A JP2008520697A5 JP 2008520697 A5 JP2008520697 A5 JP 2008520697A5 JP 2007543254 A JP2007543254 A JP 2007543254A JP 2007543254 A JP2007543254 A JP 2007543254A JP 2008520697 A5 JP2008520697 A5 JP 2008520697A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- composition
- optionally substituted
- group
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 52
- 239000000203 mixture Substances 0.000 claims 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- 125000001931 aliphatic group Chemical group 0.000 claims 11
- -1 2,5-dimethoxyphenyl Chemical group 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 claims 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 2
- 208000028389 Nerve injury Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 230000008642 heat stress Effects 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 230000008764 nerve damage Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000001847 2-phenylcyclopropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 101710138657 Neurotoxin Proteins 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000036982 Spinal cord ischaemia Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 210000005013 brain tissue Anatomy 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 claims 1
- 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000002581 neurotoxin Substances 0.000 claims 1
- 231100000618 neurotoxin Toxicity 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- MGJBERWKPZUCJM-UHFFFAOYSA-N CN(C(C1CC1)=S)NC(CC(NN(C)C(C1CC1)=S)=O)=O Chemical compound CN(C(C1CC1)=S)NC(CC(NN(C)C(C1CC1)=S)=O)=O MGJBERWKPZUCJM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62959504P | 2004-11-19 | 2004-11-19 | |
| US60/629,595 | 2004-11-19 | ||
| PCT/US2005/041750 WO2006055747A2 (en) | 2004-11-19 | 2005-11-17 | Bis(thio-hydrazide amides) for increasing hsp70 expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008520697A JP2008520697A (ja) | 2008-06-19 |
| JP2008520697A5 true JP2008520697A5 (OSRAM) | 2009-01-08 |
| JP5204489B2 JP5204489B2 (ja) | 2013-06-05 |
Family
ID=36204038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543254A Expired - Fee Related JP5204489B2 (ja) | 2004-11-19 | 2005-11-17 | Ｈｓｐ７０発現を増加するためのビス（チオ‐ヒドラジドアミド） |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8148426B2 (OSRAM) |
| EP (1) | EP1827410A2 (OSRAM) |
| JP (1) | JP5204489B2 (OSRAM) |
| AU (1) | AU2005306471B2 (OSRAM) |
| CA (1) | CA2587598A1 (OSRAM) |
| WO (1) | WO2006055747A2 (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI297335B (en) * | 2001-07-10 | 2008-06-01 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| TWI332943B (en) * | 2001-07-10 | 2010-11-11 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| TWI252847B (en) * | 2001-07-10 | 2006-04-11 | Synta Pharmaceuticals Corp | Synthesis of taxol enhancers |
| TWI330079B (en) | 2003-01-15 | 2010-09-11 | Synta Pharmaceuticals Corp | Treatment for cancers |
| ES2430373T3 (es) * | 2004-06-23 | 2013-11-20 | Synta Pharmaceuticals Corp. | Sales de bis(tio-hidrazida amida) para tratamiento de cánceres |
| WO2006113493A2 (en) * | 2005-04-15 | 2006-10-26 | Synta Pharmaceuticals Corp. | Methods of determining cancer prognosis via natural killer cell activity |
| AU2006236534A1 (en) * | 2005-04-15 | 2006-10-26 | Synta Pharmaceuticals Corp. | Methods of increasing natural killer cell activity for therapy |
| WO2006113695A1 (en) * | 2005-04-15 | 2006-10-26 | Synta Pharmaceuticals Corp. | Combination cancer therapy with bis(thiohydrazide) amide compounds |
| NZ563124A (en) * | 2005-05-16 | 2010-12-24 | Synta Pharmaceuticals Corp | Synthesis of bis(thio-hydrazide amide) salts |
| JP2009504740A (ja) * | 2005-08-16 | 2009-02-05 | シンタ ファーマシューティカルズ コーポレーション | ビス（チオ−ヒドラジドアミド）製剤 |
| EP2061451A2 (en) * | 2006-08-21 | 2009-05-27 | Synta Pharmaceuticals Corporation | Bis(thiohydrazide amides) for treating melanoma |
| US20100068174A1 (en) * | 2006-08-21 | 2010-03-18 | Synta Pharmaceuticals Corp. | Combination with bis (thiohydrazide amides) for treating cancer |
| JP2010501559A (ja) * | 2006-08-21 | 2010-01-21 | シンタ ファーマシューティカルズ コーポレーション | 黒色腫の再発を予防するまたは遅らせるのに使用するためのビス（チオヒドラジドアミド） |
| WO2008024303A2 (en) | 2006-08-21 | 2008-02-28 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| WO2008024298A1 (en) * | 2006-08-21 | 2008-02-28 | Synta Pharmaceuticals Corp. | Bis(thiohydrazide amides) for inhibiting angiogenesis |
| EP2076254A2 (en) | 2006-08-31 | 2009-07-08 | Synta Pharmaceuticals Corporation | Combination with bis(thiohydrazide amides) for treating cancer |
| US9498528B2 (en) * | 2006-09-13 | 2016-11-22 | Genzyme Corporation | Treatment of multiple sclerosis (MS) |
| US7645904B2 (en) | 2006-09-15 | 2010-01-12 | Synta Pharmaceuticals Corp. | Purification of bis(thiohydrazide amides) |
| WO2008136976A2 (en) | 2007-04-30 | 2008-11-13 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| TW200922550A (en) | 2007-08-07 | 2009-06-01 | Synta Pharmaceuticals Corp | Compounds for treating proliferative disorders |
| US8618170B2 (en) | 2007-11-09 | 2013-12-31 | Synta Pharmaceuticals Corp. | Oral formulations of bis(thiohydrazide amides) |
| US7956051B2 (en) * | 2008-01-24 | 2011-06-07 | Allergan, Inc. | Therapeutic amides and related compounds |
| US8581004B2 (en) | 2008-02-21 | 2013-11-12 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| WO2009123704A2 (en) * | 2008-03-31 | 2009-10-08 | Synta Pharmaceuticals Corp. | Process for preparing bis(thiohydrazide amides) |
| JP2012506444A (ja) | 2008-10-22 | 2012-03-15 | シンタ ファーマシューティカルズ コーポレーション | ビス［チオヒドラジドアミド］化合物の遷移金属錯体 |
| WO2010048284A1 (en) | 2008-10-22 | 2010-04-29 | Synta Pharmaceuticals Corp. | Transition metal complexes of bis[thiohydrazide amide] compounds |
| US8525776B2 (en) * | 2008-10-27 | 2013-09-03 | Lenovo (Singapore) Pte. Ltd | Techniques for controlling operation of a device with a virtual touchscreen |
| JP5631327B2 (ja) | 2008-12-01 | 2014-11-26 | シンタ ファーマシューティカルズ コーポレーション | 増殖性障害を治療するための化合物 |
| WO2011069159A2 (en) | 2009-12-04 | 2011-06-09 | Synta Pharmaceuticals Corp. | Bis[thiohydrazide amide] compounds for treating leukemia |
| US8815945B2 (en) | 2010-04-20 | 2014-08-26 | Masazumi Nagai | Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers |
| US20130149392A1 (en) * | 2011-12-12 | 2013-06-13 | Synta Pharmaceuticals Corp. | Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds |
| AU2019300031B2 (en) * | 2018-07-12 | 2025-06-12 | The Texas A&M University System | Compositions for the treatment of copper deficiency and methods of use |
| MX2022008627A (es) | 2020-01-13 | 2022-11-08 | Verge Analytics Inc | Pirazolo-pirimidinas sustituidas y usos de las mismas. |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2097737A5 (en) | 1970-07-14 | 1972-03-03 | Berlin Chemie Veb | Virustatic 4-substd 1-acylthiosemicarbazides -from carboxylic acid - hydrazide and isothiocyanates or from carboxylic acid chloride and 4- |
| DE2037257A1 (en) | 1970-07-28 | 1972-02-03 | Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt | Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn |
| GB1272920A (en) | 1971-03-15 | 1972-05-03 | Berlin Chemie Veb | New thiosemicarbazides |
| US4012360A (en) * | 1973-12-03 | 1977-03-15 | Ciba-Geigy Corporation | Bis-salicyloyl-dicarboxylic acid dihydrazides as stabilizers for polyolefines |
| JPS5091056A (OSRAM) | 1973-12-17 | 1975-07-21 | ||
| US6013836A (en) * | 1992-02-28 | 2000-01-11 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-disubstitutedhydrazines |
| FR2697752B1 (fr) | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| JP3535177B2 (ja) * | 1995-09-22 | 2004-06-07 | バイオイメージ・アクティーゼルスカブ | 緑色蛍光性タンパクであるｇｆｐの新規な変種 |
| US6235787B1 (en) * | 1997-06-30 | 2001-05-22 | Hoffmann-La Roche Inc. | Hydrazine derivatives |
| GB9727524D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Synergistic antitumor composition containing a biologically active ureido compound |
| TW479053B (en) * | 1998-10-19 | 2002-03-11 | Agro Kanesho Co Ltd | Hydrazineoxoacetamide derivatives and pesticides |
| ES2161594B1 (es) * | 1998-12-17 | 2003-04-01 | Servier Lab | Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. |
| US6322303B1 (en) * | 2000-05-12 | 2001-11-27 | David M. John | Dunnage bag and method of making same |
| EP1164126A1 (de) * | 2000-06-16 | 2001-12-19 | Basf Aktiengesellschaft | Salicylsäurehydrazid-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung zur Bekämpfung von Schadpilzen |
| US6365745B1 (en) * | 2000-07-14 | 2002-04-02 | Sumika Fine Chemicals Co., Ltd. | Method for producing hydrazine derivative |
| CA2435829A1 (en) * | 2001-01-25 | 2002-08-01 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| US6602907B1 (en) * | 2001-06-08 | 2003-08-05 | University Of Central Florida | Treatment of breast cancer |
| US6924312B2 (en) * | 2001-07-10 | 2005-08-02 | Synta Pharmaceuticals Corp. | Taxol enhancer compounds |
| TWI252847B (en) * | 2001-07-10 | 2006-04-11 | Synta Pharmaceuticals Corp | Synthesis of taxol enhancers |
| TWI332943B (en) * | 2001-07-10 | 2010-11-11 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| TWI297335B (en) * | 2001-07-10 | 2008-06-01 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| TW200408407A (en) * | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
| TWI330079B (en) * | 2003-01-15 | 2010-09-11 | Synta Pharmaceuticals Corp | Treatment for cancers |
| ES2430373T3 (es) * | 2004-06-23 | 2013-11-20 | Synta Pharmaceuticals Corp. | Sales de bis(tio-hidrazida amida) para tratamiento de cánceres |
| US20060142393A1 (en) * | 2004-09-16 | 2006-06-29 | Sherman Matthew L | Bis(thio-hydrazide amides) for treatment of hyperplasia |
| US20060167106A1 (en) * | 2004-11-19 | 2006-07-27 | Mei Zhang | Compounds acting at the centrosome |
| WO2006113695A1 (en) | 2005-04-15 | 2006-10-26 | Synta Pharmaceuticals Corp. | Combination cancer therapy with bis(thiohydrazide) amide compounds |
| WO2006113493A2 (en) | 2005-04-15 | 2006-10-26 | Synta Pharmaceuticals Corp. | Methods of determining cancer prognosis via natural killer cell activity |
| AU2006236534A1 (en) | 2005-04-15 | 2006-10-26 | Synta Pharmaceuticals Corp. | Methods of increasing natural killer cell activity for therapy |
| NZ563124A (en) * | 2005-05-16 | 2010-12-24 | Synta Pharmaceuticals Corp | Synthesis of bis(thio-hydrazide amide) salts |
| JP2009504740A (ja) * | 2005-08-16 | 2009-02-05 | シンタ ファーマシューティカルズ コーポレーション | ビス（チオ−ヒドラジドアミド）製剤 |
-
2005
- 2005-11-17 AU AU2005306471A patent/AU2005306471B2/en not_active Ceased
- 2005-11-17 CA CA002587598A patent/CA2587598A1/en not_active Abandoned
- 2005-11-17 JP JP2007543254A patent/JP5204489B2/ja not_active Expired - Fee Related
- 2005-11-17 WO PCT/US2005/041750 patent/WO2006055747A2/en not_active Ceased
- 2005-11-17 EP EP05824349A patent/EP1827410A2/en not_active Withdrawn
- 2005-11-17 US US11/281,923 patent/US8148426B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008520697A5 (OSRAM) | ||
| JP2008504264A5 (OSRAM) | ||
| JP2008536875A5 (OSRAM) | ||
| JP2012509903A5 (OSRAM) | ||
| JP2010529203A5 (OSRAM) | ||
| CA2512797A1 (en) | Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer | |
| JP2004531517A5 (OSRAM) | ||
| JP2019518766A5 (OSRAM) | ||
| JP2017526677A5 (OSRAM) | ||
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| RU2009109949A (ru) | Соединения для лечения пролиферативных расстройств | |
| JP2010501562A5 (OSRAM) | ||
| JP2010501584A5 (OSRAM) | ||
| RU2007101898A (ru) | Соли бис (тиогидразидамида) для лечения рака | |
| JP2011509309A5 (OSRAM) | ||
| JP2018505898A5 (OSRAM) | ||
| JP2020502047A5 (OSRAM) | ||
| JP2014511891A5 (OSRAM) | ||
| JP2009527462A5 (OSRAM) | ||
| JP2014511892A5 (OSRAM) | ||
| RU2008145971A (ru) | Производные 2-тиоксантина, действующие в качестве ингибиторов мро | |
| JP2013521291A5 (OSRAM) | ||
| JP2019510082A5 (OSRAM) | ||
| RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
| JP2007533722A5 (OSRAM) |